Top Stories
RNA interactions may hold key to drugs targeting SARS-CoV-2
Researchers have unearthed how the SARS-CoV-2 virus employs genomic "origami" to infect and replicate inside host cells, a discovery that may hold the key to developing novel antiviral drugs that target specific areas of the virus's genomic structure. The findings were published on November 5 in Molecular Cell.
|
|
|
Different immune response helps kids clear SARS-CoV-2 quickly
Why does the SARS-CoV-2 virus seem to have less of an impact on children than adults? A new study published November 5 in Nature Immunology investigates this question, finding that the immune systems of children respond differently to SARS-CoV-2 in a way that allows them to more easily clear the virus from their bodies.
|
|
|
|
Cancer & Disease Research Sponsored by Beckman Coulter
Novartis COVID-19 mAb fails to meet clinical trial endpoints
Novartis has released new data from an interim analysis of its randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of canakinumab (Ilaris), a monoclonal antibody (mAb) in hospitalized patients with COVID-19.
|
|
|
Proteomic changes in cancer cells provide new drug insights
Large-scale profiling of protein changes in response to drug treatment in cancer cell lines has been demonstrated as a powerful tool to predict drug sensitivity, understand drug resistance, and identify optimal drug combinations. The analysis was published in Cancer Cell on November 5.
|
|
|
|
Cell Biology
Drug Discovery & Development
Genomics Sponsored by Nvidia
RNA interactions may hold key to drugs targeting SARS-CoV-2
Researchers have unearthed how the SARS-CoV-2 virus employs genomic "origami" to infect and replicate inside host cells, a discovery that may hold the key to developing novel antiviral drugs that target specific areas of the virus's genomic structure. The findings were published on November 5 in Molecular Cell.
|
|
|
|
Immunology Sponsored by Beckman Coulter
What Your Colleagues are Buzzing About
|